ATE387186T1 - Neue zusammensetzungen von sildenafil-freier base - Google Patents

Neue zusammensetzungen von sildenafil-freier base

Info

Publication number
ATE387186T1
ATE387186T1 AT04786037T AT04786037T ATE387186T1 AT E387186 T1 ATE387186 T1 AT E387186T1 AT 04786037 T AT04786037 T AT 04786037T AT 04786037 T AT04786037 T AT 04786037T AT E387186 T1 ATE387186 T1 AT E387186T1
Authority
AT
Austria
Prior art keywords
free base
sildenafil free
new compositions
sildenafil
compositions
Prior art date
Application number
AT04786037T
Other languages
English (en)
Inventor
Tuula Ryde
Douglas Hovey
H Bosch
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Application granted granted Critical
Publication of ATE387186T1 publication Critical patent/ATE387186T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
AT04786037T 2003-07-23 2004-07-23 Neue zusammensetzungen von sildenafil-freier base ATE387186T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48910103P 2003-07-23 2003-07-23

Publications (1)

Publication Number Publication Date
ATE387186T1 true ATE387186T1 (de) 2008-03-15

Family

ID=34135095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04786037T ATE387186T1 (de) 2003-07-23 2004-07-23 Neue zusammensetzungen von sildenafil-freier base

Country Status (8)

Country Link
US (1) US20050042177A1 (de)
EP (1) EP1658053B1 (de)
JP (1) JP4860469B2 (de)
AT (1) ATE387186T1 (de)
CA (1) CA2533163A1 (de)
DE (1) DE602004012117T2 (de)
ES (1) ES2302035T3 (de)
WO (1) WO2005013937A2 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
DK1471887T3 (da) * 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
WO2004087243A1 (ja) 2003-03-27 2004-10-14 Bioactis Limited 鼻腔用粉末薬剤施薬装置
US7618976B2 (en) 2004-01-05 2009-11-17 Teva Pharmaceutical Industries Ltd Methods for the production of sildenafil base and citrate salt
CA2568524A1 (en) 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
AU2012201630B8 (en) * 2004-12-31 2014-03-06 Iceutica Pty Ltd NanoParticle Composition(s) and Method for Synthesis Thereof
WO2006069419A1 (en) * 2004-12-31 2006-07-06 Iceutica Pty Ltd Nanoparticle composition and methods for synthesis thereof
WO2006074443A2 (en) 2005-01-07 2006-07-13 The Johns Hopkins University Pde5 inhibitor compositions and methods for immunotherapy
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
DE102005016981A1 (de) * 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
JP2008540546A (ja) * 2005-05-10 2008-11-20 エラン ファーマ インターナショナル リミテッド ナノ粒子クロピドグレル製剤
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
CN101232870A (zh) * 2005-06-03 2008-07-30 伊兰制药国际有限公司 纳米微粒甲磺酸伊马替尼制剂
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
US20060292214A1 (en) * 2005-06-03 2006-12-28 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
CA2612994A1 (en) 2005-06-08 2006-12-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cefditoren
ATE446742T1 (de) * 2005-06-09 2009-11-15 Elan Pharma Int Ltd Nanopartikuläre ebastinformulierungen
CA2611741A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
US20100221327A1 (en) * 2005-06-15 2010-09-02 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
US20070031349A1 (en) * 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors
ATE398451T1 (de) * 2005-08-29 2008-07-15 Teva Pharma Festes, teilchenförmiges tadalafil mit bimodaler teilchengrössenverteilung
WO2007033239A2 (en) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
EP1968705A1 (de) * 2005-12-21 2008-09-17 Pfizer Products Incorporated Pharmazeutische kombinationen eines pde-5-hemmers und eines 5-alpha-reduktase-hemmers
EA019879B1 (ru) 2005-12-29 2014-07-30 Лексикон Фармасьютикалз, Инк. Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
CN101495096A (zh) 2006-05-30 2009-07-29 伊兰制药国际有限公司 纳米微粒泊沙康唑制剂
WO2008000042A1 (en) 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
CA2657379A1 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
MX2009000391A (es) * 2006-07-12 2009-06-30 Elan Pharma Int Ltd Formulación de modafinilo en forma de nano-partículas.
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
BRPI0806876A2 (pt) * 2007-01-22 2014-04-29 Novavax Inc Formulações farmacêuticas multifásicas de fármacos pobremente solúveis em água para variabilidade reduzida de alimentação/jejum e biodisponibilidade oral aprimorada
KR100920106B1 (ko) * 2007-11-14 2009-10-01 경북대학교 산학협력단 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치
KR20110007095A (ko) * 2008-03-21 2011-01-21 엘란 파마 인터내셔널 리미티드 이마티니브의 부위-특이적 전달을 위한 조성물 및 사용방법
KR101004205B1 (ko) * 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
UA106231C2 (uk) 2009-04-24 2014-08-11 Айсьютика Пти Лтд Разова доза фармацевтичної композиції індометацину (варіанти)
EP2429495A4 (de) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd Intranasale pharmazeutische zusammensetzung mit verbesserter pharmakokinetik
WO2010138539A2 (en) 2009-05-27 2010-12-02 Elan Pharma International Ltd. Reduction of flake-like aggregation in nanoparticulate active agent compositions
CN102497857A (zh) * 2009-06-19 2012-06-13 纳米模型匈牙利有限公司 纳米结构的西地那非碱、其药学可接受的盐和共结晶、它们的组合物、其制备方法和包含它们的药物组合物
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
JP2013510092A (ja) 2009-11-05 2013-03-21 レクシコン ファーマシューティカルズ インコーポレイテッド がんの治療のためのトリプトファンヒドロキシラーゼ阻害剤
CA2789229A1 (en) 2010-02-10 2011-08-18 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
WO2011156405A2 (en) * 2010-06-07 2011-12-15 Novadel Pharma Inc. Oral spray formulations and methods for administration of sildenafil
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102127182B (zh) * 2010-12-23 2012-07-04 南京医科大学 用于检测pde-5抑制剂的磁性分子印记聚合物的制备方法
MX349803B (es) * 2011-02-11 2017-08-14 Ctc Bio Inc Preparación farmacéutica de película que contiene sildenafil en su forma de base libre y método para producir dicha preparación.
US20130303763A1 (en) 2012-03-30 2013-11-14 Michael D. Gershon Methods and compositions for the treatment of necrotizing enterocolitis
FR2999086B1 (fr) * 2012-12-10 2015-04-10 Ethypharm Sa Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
WO2014125343A1 (en) * 2013-02-12 2014-08-21 Alembic Pharmaceuticals Limited Tadalafil tablet composition with reduced dose strength
CA2918291C (en) 2013-07-22 2022-12-06 Universite Du Quebec A Chicoutimi Use of plant extracts against herpes simplex virus
EP3082428A4 (de) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5-inhibitorpulverformulierungen und zugehörige verfahren
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2017168174A1 (en) * 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
KR101778688B1 (ko) 2016-05-31 2017-09-15 한양대학교 에리카산학협력단 포스포다이에스터라제―5 억제제를 포함하는 약제학적 복합제제
WO2018142189A1 (en) 2017-02-02 2018-08-09 Dukebox Sp. Z O. O. A method of manufacturing a suspension of nanoparticles of tadalafil or sildenafil citrate
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
AU2018397436A1 (en) 2017-12-26 2020-08-13 Ftf Pharma Private Limited Liquid oral formulations for PDE V inhibitors
GR1009643B (el) * 2018-06-25 2019-11-12 Arvo Μονοπροσωπη Ι.Κ.Ε. Νεες συνθεσεις φαρμακευτικων σκευασματων σιλδεναφιλης μειωμενης περιεκτικοτητας σε δραστικη ουσια και νεες χρησεις τους
CN112972405B (zh) * 2019-12-02 2022-12-27 北京兴源联合医药科技有限公司 一种他达拉非冻干口腔崩解片及其制备方法
CN112972404A (zh) * 2019-12-02 2021-06-18 北京兴源联合医药科技有限公司 一种西地那非冻干口腔崩解片及其制备方法
EP3928772B1 (de) 2020-06-26 2024-06-19 Algiax Pharmaceuticals GmbH Nanopartikuläre zusammensetzung
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
EP4243796A4 (de) * 2020-11-16 2025-01-22 Orcosa Inc. Verbesserte verwendung von cannabinoiden bei der behandlung von epilepsie
WO2023037394A1 (en) * 2021-09-13 2023-03-16 Amman Pharmaceutical Industries Company A pharmaceutical composition of sildenafil and a formulation thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315356A1 (de) * 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka Verwendung von prostaglandinanalogen
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6531114B1 (en) * 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US20010053780A1 (en) * 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
AU3048501A (en) * 1999-11-18 2001-05-30 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
AU2001264977B2 (en) * 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
EP1301186A1 (de) * 2000-07-19 2003-04-16 Lavipharm Laboratories, Inc. Sildenafilcitrat-festdispersionen mit hoher wasserlöslichkeit
US6548508B2 (en) * 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
AU2002310086B2 (en) * 2001-05-24 2008-09-04 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US7766013B2 (en) * 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP2283864A1 (de) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Flüssige Zusammensetzung enthaltend stabilisierte Wirkstoff-Nanopartikeln
GB0219516D0 (en) * 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil

Also Published As

Publication number Publication date
US20050042177A1 (en) 2005-02-24
DE602004012117D1 (de) 2008-04-10
CA2533163A1 (en) 2005-02-17
ES2302035T3 (es) 2008-07-01
WO2005013937A2 (en) 2005-02-17
JP2006528176A (ja) 2006-12-14
JP4860469B2 (ja) 2012-01-25
WO2005013937A3 (en) 2005-06-16
EP1658053B1 (de) 2008-02-27
EP1658053A2 (de) 2006-05-24
DE602004012117T2 (de) 2009-02-26

Similar Documents

Publication Publication Date Title
DE602004012117D1 (de) Neue zusammensetzungen von sildenafil-freier base
ATE415946T1 (de) Neue metaxalon-zusammensetzungen
ATE419835T1 (de) Nystatin-nanopartikelzusammensetzungen
CY1113036T1 (el) Φαρμακοτεχνικες μορφες νανοσωματιδιων μεγεστρολης
WO2005002542A3 (en) Nanoparticulate meloxican formulations
SG161203A1 (en) Nanoparticulate tacrolimus formulations
EA200401556A1 (ru) Препараты на основе наночастиц фибрата
EA200702638A1 (ru) Стабильная композиция (рецептура) с наночастицами ацетаминофена
ATE343376T1 (de) Nanopartikelzusammensetzungen von angiogeneseinhibitoren
ATE385777T1 (de) Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren
MXPA05007635A (es) Composicion para la limpieza personal que contiene particulas de forma irregular y particulas esfericas.
ATE395042T1 (de) Darreichungsformen welche mikropartikel und treibgas enthalten
EA200801468A1 (ru) Препараты ганаксолона и способы их получения и применения
DE50305305D1 (de) Natriumpercarbonatpartikel mit verbesserter lagerstabilit t
DE60310936D1 (de) Riechstoffzusammensetzung
NO20080403L (no) Nanopartikulaere megestrolformuleringer
DE60226916D1 (de) Shampoo mit hohlen Teilchen
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
ATE359765T1 (de) Verringerung der teilchengrösse von bioaktiven verbindungen
PT1453380E (pt) Composicoes contendo sacarido e silica hidrofobica
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties